Oct 09, 2024 8:27am EDT DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Aug 07, 2024 4:15pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Aug 01, 2024 8:20am EDT DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Jul 11, 2024 8:00am EDT DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Jun 26, 2024 8:00am EDT DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
May 08, 2024 4:30pm EDT DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
May 02, 2024 8:55am EDT DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024